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Abstract 
Phenylketonuria (PKU) is an autosomal recessive disease which results from mutations in the phenylalanine hydroxy-
lase (PAH) gene. The aim of this study was the identification of sixteen different mutations in Iranian patients with 
hyperphenylalaninemia. The mutations were detected during the characterization of PAH genotypes of 39 PKU 
patients from Qazvin and Zanjan provinces of Iran. PAH mutations have been analyzed by PCR and direct sequenc-
ing of PCR products of the promoter region and all 13 exons of PAH gene, including the splicing sites. A mutation 
detection rate of 74.3 % was realized. Two mutations were found at high frequencies: R176X (10.25 %) and p.P281L 
(10.25 %). The frequencies of the other mutations were: IVS2+5G>A (2.56 %), IVS2+5G>C (2.56 %), p.L48S (2.56 %), 
p.R243Q (2.56 %), p.R252Q (5.12 %), p.R261Q (7.69 %), p.R261X (5.12 %), p.E280K (2.56 %), p.I283N (2.56 %), IVS9+5G>A 
(2.56 %), IVS9+1G>A (1.28 %), IVS11+1G>C (1.28 %), p.C357R (1.28 %), c.632delC (2.56 %). The present results confirm 
the high heterogeneity of the PAH locus and contribute to information about the distribution and frequency of PKU 
mutations in the Iranian population.
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Background
Deficiency of hepatic phenylalanine hydroxylase (PAH) 
[EC.1.14.16.1], which converts phenylalanine to tyrosine, 
is the major frequent cause of hyperphenylalaninemia 
(Guldberg et al. 1998). This enzyme defect, causes toxic 
accumulation of phenylalanine in the body fluids and 
damage to the nervous system that can result in growth 
failure, microcephaly, mental retardation and neurobe-
havioral abnormalities (Zhang et al. 2005). Phenylketonu-
ria (PKU) is one of the most common inborn disease of 
amino acid metabolism, characterized by mutation of 
the PAH gene (Williams et al. 2008). According the lev-
els of phenylalanine, they are four categories: mild hyper-
phenylalaninemia (HPA), mild PKU, moderate-PKU, 
and classic-PKU. Classical PKU is the most severe form 
of this disorder. A phenylalanine restricted diet, can be 
useful to prevent the neurotoxic complication of Phe and 
its metabolites (Olsson et  al. 2007). The prevalence of 
PKU varies worldwide. In Caucasians, the prevalence is 
about 1/10,000 live births (Olsson et al. 2007), while that 
in Iranian population was 1/3627 (Koochmeshgi et  al. 
2002). In fact, the high rate of consanguineous marriages 
in Iran may be a contributing factor to the high incidence. 
The human PAH gene is located on chromosome 12q23.2 
and is 90 kb in size with 13 exons and 12 introns (Santos 
et  al. 2010). So far, several hundred different mutations 
in this gene have been identified in PKU patients and 
listed in the PAH mutation Analysis Consortium data-
base (http://www.Pahdb.mcgill.ca). The most frequently 
occurring type of these mutations are missense muta-
tions (Scriver 2007). The PAH gene mutations demon-
strate considerable ethnic groups and geographic areas 
variation (Zschocke 2003). Previous studies have shown 
a correlation between PAH genotype and metabolic phe-
notype in PKU and have suggested the phenotypic rela-
tions of particular mutation combinations (Desviat et al. 
1997; Kayaalp et al. 1997; Romano et al. 1996). Mutation 
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analysis of a given population can be useful for the better 
understanding functional aspects of mutant protein and 
the relationship between genotype/phenotype.
Objectives
The purpose of this study was to identify the molecular 
basis of PKU in Iranian Patients. In addition, we exam-
ined the variation in all 13 exons of the PAH gene in 39 
patients, predominantly from Qazvin and Zanjan prov-
inces of Iran.
Patients and methods
Thirty- nine unrelated children with PAH deficiency were 
enrolled for this study after obtaining informed consent 
from the parents. A total of 39 patients, 24 cases were 
from the province of Qazvin and 15 cases from the Zan-
jan region. The PAH activity was measured by conven-
tional biochemical methods. Most of the patients were 
identified when they showed mental retardation and few 
patients were identified during neonatal screening. The 
subjects were with ages ranging from 1 month to 10 years 
old. The clinical criteria were classical PKU with blood 
phenylalanine concentrations >20  mg/dl (>1200  µm/L) 
(Guttler 1980). The study was approved by the ethics 
committee of Qazvin University of medical sciences.
DNA analysis
Genomic DNA was isolated from the leukocytes in blood 
samples using a DNA purification Qiagen kit (Valencia, 
CA, USA). All 13 PAH exons and their flanking intronic 
sequences were amplified by PCR using primers designed 
by primer 3 software. The primers sequences can be pro-
vided upon request. PCR reaction were performed on the 
Gene AMP PCR System Verity, (Foster City, CA, USA). 
The PCR condition were 95  °C for 3  min, 30 cycles of 
95 °C for 30 s, 45–60 °C for 30 s, 72 °C for 30 s followed 
by 72 °C for 5 min. Samples were electrophoresed in 2 % 
agarose gel. The PCR products were sequenced by ABI 
prism 3130 genetic analyzer (Applied Biosystems, USA) 
and compared with the human genomic DNA sequence 
in GenBank to identify the mutations.
Results
In this study, we detected causative mutations on 49 
of the 78 mutant alleles (diagnostic efficiency 74.3  %) 
(Table  1). These included: eight missense mutations 
(50 %), five splice mutations (31 %), two nonsense muta-
tions (12.5 %) and one deletion (6.25 %) (Table 1). Exon 
7, 6, 2 and the flanking intronic regions include 85.5 % of 
the mutant alleles. The p.R176X and p.P281L mutations 
were the most frequent (10.5  %) followed by p.R261Q 
(7.69 %), p.R261X and p.R252Q (5.12 %), accounting for 
nearly 40  % of all mutations. Mutations p.R261X and 
p.R252Q were less frequent. All other mutations had 
frequencies less than 3 %. Among the 39 unrelated fami-
lies studied, 20 (51.2  %) were homozygote, 6 (15.3  %) 
heterozygote and 2 (5.12  %) were compound heterozy-
gote and 11 (28.2  %) were no PKU- causing mutations. 
The following polymorphisms were detected in the PAH 
gene: p.L385L, p.Q232Q and p.V245V with the frequency 
of 84, 51 and 17 % respectively were shown the highest 
prevalence among the other polymorphisms (Table  2). 
Genotypes of 39 PKU patients are shown in Table 3.
Discussion
In this study, we identified mutations in the PAH gene 
and to evaluate the genetic heterogeneity of PKU disease 
in 39 unrelated Iranian patients who had been referred to 
Qazvin and Zanjan provinces. From this experiment, 28 
of 39 PKU patients were found to contain the mutation. 
Our analysis of the homozygosity of the mutations were 
nearly similar to that observed in northwestern Iranian 
populations (Bonyadi et al. 2010). The majority of the rec-
ognized mutations are situated in the catalytic domains 
(143–410 amino acid), and some of them (p.P281L, 
R252W) are located in the cofactor binding regions. 
The most common mutation in our samples is P.P281L. 
This data agreement with what was found in other group 
Iran (Bonyadi et  al. 2010; Hamzehloei et  al. 2012). The 
P.P281L mutation in exon 7 with a relative frequency of 
10.5 % is C → T substitution lead to conversation of Pro 
to Leu at codon 281 of PAH. The another major muta-
tion in our study was p.R176X (10.25 %), which is simi-
lar to the data obtained in population of Khorasan Razavi 
origin (Hamzehloei et  al. 2012).Previous study on the 
genotype/phenotype association demonstrated generally 
a positive correlation between R176X mutation and clas-
sic phenotype(Acosta et al. 2001; Bueno et al. 2013). Sev-
eral studies reported that the IVS10-11G>A mutation, 
a splice mutation in the end of intron 10, observed with 
a high incidence among in the Mediterranean region, 
Brazil and some parts of Iran including: East Azarbai-
jan, Semnan, Khorasan Razavi, Hamedan (Dianzani et al. 
1995; Kleiman et al. 1994; Rivera et al. 1998; Zare-Karizi 
et al. 2011), however this mutation was not found in the 
present study. The virtual absence of this mutation in 
our study may reflect the regional variability of popula-
tions. The second most frequent mutation identified in 
present study, R261Q (7.69 %) occurs on a CpG mutation 
hotspot on exon 7, leads to the conversion of Arg to Gln 
at codon 261 of PAH. This mutation is a common muta-
tion in the Mediterranean and southern Europe but has 
a very low incidence in Spain (Couce et al. 2013; Loeber 
2007; Perez et  al. 1994; Rivera et  al. 1998; Rivera et  al. 
2011). Furthermore, the frequency of R243Q mutation 
has been reported to be 18.2  % in Chinese and 12  % in 
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Koreans, whiles in the present study the frequency of this 
mutation was found to be 2.5 % (Song et al. 2005). Most 
mutant PAH alleles probably with influencing on PAH 
gene transcription and translation can decrease the intra-
cellular stability of protein and finally reduce enzyme 
function completely. In this study, we also analyzed the 
association between mutations and polymorphisms. The 
c.755G>A mutation located on the same allele with the 
c.168+19T>C polymorphism. Also, we observed associa-
tion between the p.Q232Q polymorphism and c.842C>T, 
C781C>T, c.782G>A, c.755G>A, c.526C>T mutations 
occurred on the same allele in cis form, that particularly 
in the final case,similar associations have been reported 
in previous study (Hamzehloei et al. 2012). The majority 
of mutant alleles (73 %) were located on exon 7 and 6 that 
is in agreement with previous studies in Iranian popula-
tions (Hamzehloei et  al. 2012; Zare-Karizi et  al. 2011).
In addition, the novel gene variant c.1069T>C (p.C357R) 
has been seen in Iranian population for the first time. 
Thereby to plan detection strategy; the samples will be 
screened first for mutations in these regions. If mutations 
were not identified, the other exons and their adjacent 
will be tested.
Conclusion
Our results of Iranian individuals with PKU confirm a 
heterogeneous spectrum of mutations, displaying dif-
ferent ethnic and geographical origins. Moreover, our 
Table 1 Spectrum and frequency of PAH mutations identified in 39 patients
Systematic name  
(DNA level)
Trivial name  
(protein effect)
Location Mutation  
type
Number  
of alleles
Frequency (%)
c.168+5G>A IVS2+5G>A Intron 2 Splicing 2 2.56
c.168+5G>C IVS2+5G>C Intron 2 Splicing 2 2.56
c.143T>C p.L48S Exon 2 Missense 2 2.56
c.526C>T p.R176X Exon 6 Nonsense 8 10.25
c.632delC p.P211>Hfs Exon 6 deletion 2 2.56
c.838G>A p.E280K Exon 7 Missense 2 2.56
c.782G>A p.R261Q Exon 7 Missense 6 7.69
c.842C>T p.P281L Exon 7 Missense 8 10.25
c.781C>T p.R261X Exon 7 Nonsense 4 5.12
c.755G>A p.R252Q Exon 7 Missense 4 5.12
c.728G>A p.R243Q Exon 7 Missense 2 2.56
c.848T>A p.I283N Exon 8 Missense 2 2.56
c.969+1G>A IVS9+1G>A Intron 9 Splicing 1 1.28
c.969+5G>A IVS9 +5G>A Intron 9 Splicing 2 2.56
c.1199+1G>C IVS11+1G>C Intron 11 Splicing 1 1.28
c.1069T>C p.C357R Exon 11 Missense 1 1.28
Total (number of alleles  
identified)
49 74.3
Table 2 PAH polymorphisms identified in 39 patients
Systematic name  
(DNA level)
Trivial name  
(protein effect)
Location Number  
of alleles
Frequency (%)
c.696A>G p.Q232Q Exon 6 40 51.28
c.735G>A p.V245V Exon 7 14 17.9
c.912G>A p.Q304Q Exon 8 2 2.56
c.1155C>G p.L385L Exon 11 66 84.61
c.168+19T>C IVS2+19T>C Intron 2 5 6.4
c.-71A>C 5-UTR 5-UTR 4 5.1
c.843T>A p.P281P Exon 8 2 2.56
IVS3-22C>T c.353-22C>T Intron 3 2 2.56
Number of alleles identified 135
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findings were slightly different from other ethnic groups. 
These findings can be useful to genotype/phenotype rela-
tionship in patients and provide future some ability to 
confirmatory diagnostic testing, prognosis and predict 
severity of PKU patients.
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Table 3 Distributional genotypes in 39 PKU patients
U unidentified
Genotype Polymorphism Number of patients
u/u c.168+19T>C, c.1155G>C, c.696A>G 1
c.838G>Ap.E280K/c.838G>Ap.E280K c.735G>A, c.912G>A, c.1155C>G 1
u/u c.1155C>G 1
c.782G>Ap.R261Q/c.782G>Ap.R261Q c.1155C>G 1
u/u c.735G>A, c.1155C>G 1
u/u c.168+19T>C, c.1155G>C, c.696A>G 1
c.842C>T-p.P281L/c.842C>T-p.P281L c.696A>G, c.1155C>G 2
u/u c.168+19T>C, c.1155G>C, c.696A>G 1
c.781C>T-p.R261X/c.781C>T-p.R261X c.1155C>G 1
c.755G>A-p.R252Q/U c.696A>G, c.1155C>G 1
c.842C>Tp.P281L/c.842C>Tp.P281L c.696A>G, c.1155C>G 1
u/u c.696A>G, c.1155C>G 1
c.755G>A-p.R252Q/U c.-71A>C 1
IVS9+1G>T/U c.696A>G, c.1155C>G 1
C781C>T-p.R261X/C781C>T-p.R261X c.696A>G, c.1155C>G 1
c.782G>A-p.R261Q/c.782G>A-p.R261Q c.696A>G, c.1155C>G 2
c.755G>A-p.R252Q/c.755G>A-p.R252Q c.696A>G, c.1155C>G, c.168+19T>C 1
c.526C>T-p.R176X/c.526C>T-p.R176X c.-71A>C 1
c.526C>Tp.R176X/c.526C>Tp.R176X c.1155C>G 1
c.143T>C, p.L48S/c.143T>C, p.L48S c.1155C>G 1
u/u c.1155C>G 1
IVS2+5G>A/IVS2+5G>A 1
c.848T>A-p.I283N/c.848T>A-p.I283N 1
u/u c.168+19T>C, c.1155C>G 1
c.526C>T-p.R176X/c.526C>T-p.R176X c.696A>G, c.1155C>G 2
c.842C>T-p.P281L/IVS11+1G>C c.696A>G, c.1155C>G 1
c.842C>T-p.P281L/c.842C>T-p.P281L c.696A>G, c.1155C>G 1
c.632delC p.P211>Hfs/c.632delC p.P211>Hfs c.1155C>G, c.735 G>A 1
u/u c.735G>A, c.1155C>G 1
c.728G>A-p.R243Q/U c.735G>A, c.1155C>G 1
IVS9+5G>A/U c.735G>A, c.1155C>G 1
IVS9+5G>A/U c.696A>G, c.1155C>G 1
c.728G>A-p.R243Q/c.1069T>C-p.C357R c735G>A 1
u/u c.696A>G, c.1155C>G 1
IVS2+5G>C/IVS2+5G>C c.696A>G, c.843T>A, c.1155C>G 1
u/u c.735G>A, IVS3-22C>T 1
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